Health
Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test – News-Medical.net
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce…
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical sensitivity with laboratory samples.
Avacta is developing several coronavirus tests using Affimer binders that are highly…
-
General23 hours agoQueensland government strikes new deal with Bravus to defer royalties, expand Carmichael coal mine
-
Noosa News23 hours agoHeartbreaking CCTV shows father and son moments before fatal crash in Regents Park, Queensland
-
General21 hours agoTwo men involved in fatal helicopter accident charged over stealing crocodile eggs from Kakadu National Park
-
Noosa News22 hours agoFamily’s heartbreak after Trevor Doyle found dead in park in Logan